Investment Summary

Signet Healthcare Partners Invests In Ascendia Pharmaceuticals

On April 8, 2021, growth capital firm Signet Healthcare Partners invested in life science company Ascendia Pharmaceuticals

Investment Highlights
  • This is Signet Healthcare Partners’ 9th transaction in the Life Science sector.
  • This is Signet Healthcare Partners’ 7th transaction in the United States.
  • This is Signet Healthcare Partners’ 3rd transaction in New Jersey.

Investment Summary
Date 2021-04-08
Target Ascendia Pharmaceuticals
Sector Life Science
Investor(s) Signet Healthcare Partners
Deal Type Growth Capital
Advisor(s) Wombat Capital Ltd. (Financial)
Sills Cummis & Gross (Legal)

Target

Ascendia Pharmaceuticals

North Brunswick, New Jersey, United States
Ascendia Pharmaceuticals is a specialty CDMO dedicated to developing and manufacturing enhanced formulations for pre-clinical and clinical stage drug candidates and marketed drug products. Ascendia specializes in improving the solubility and bioavailability of poorly water-soluble drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, and topical routes of administration. The company has three technology platforms - EmulSol® for producing nano-emulsions, AmorSol® for creating amorphous solid dispersions, and NanoSol® for formulating nano-particles. Ascendia Pharmaceuticals was founded in 2012 and is based in North Brunswick, New Jersey.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Signet Healthcare Partners

Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1998
PE ASSETS 600M USD
Size Middle-Market
Type Sector Focused
DESCRIPTION

Signet Healthcare Partners is a growth capital firm focused on the healthcare sector. Specific areas of interest include specialty pharmaceuticals, pharmaceutical services, medical devices, and diagnostics. Signet will consider opportunities throughout North America and Europe and looks to commit $10 to $50 million per transaction. Signet Healthcare Partners was established in 1998 and is headquartered in New York, New York.

DEAL STATS #
Overall 11 of 15
Sector (Life Science) 9 of 12
Type (Growth Capital) 6 of 10
State (New Jersey) 3 of 3
Country (United States) 7 of 8
Year (2021) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-22 Altasciences

Laval, Quebec, Canada

Altasciences is a forward-thinking, mid-sized contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. Altasciences was founded in 1992 and is based in Laval, Quebec.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-24 Juno Pharmaceuticals

Mississauga, Ontario, Canada

Juno Pharmaceuticals is a specialty pharmaceutical company with a focus on injectable generic drugs sold through hospital channels. Juno Pharmaceuticals was founded in 2012 and is based in Mississauga, Ontario.

Buy -
Mergr

Product

Company

Legal